HBM Holdings Past Earnings Performance

Past criteria checks 3/6

HBM Holdings ha aumentado sus ingresos a un ritmo medio anual de 10.4%, mientras que la industria Biotechs ha visto aumentar sus ingresos growing a 15.6% anualmente. Los ingresos han crecido growing a un ritmo medio anual de 58.1%. HBM Holdings La rentabilidad de los fondos propios de la empresa es de 19% y sus márgenes netos son de 25.5%.

Key information

10.4%

Earnings growth rate

40.6%

EPS growth rate

Biotechs Industry Growth	11.0%
Revenue growth rate	58.1%
Return on equity	19.0%
Net Margin	25.5%
Last Earnings Update	31 Dec 2023

Recent past performance updates

Recent updates

HBM Holdings Limited (HKG:2142) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Jan 01

We're Not Very Worried About HBM Holdings' (HKG:2142) Cash Burn Rate

Feb 08

HBM Holdings (HKG:2142) Is In A Strong Position To Grow Its Business

May 30

Revenue Downgrade: Here's What Analysts Forecast For HBM Holdings Limited (HKG:2142)

Apr 07

Here's What Analysts Are Forecasting For HBM Holdings Limited (HKG:2142) After Its Full-Year Results

Mar 31

What Type Of Shareholders Own The Most Number of HBM Holdings Limited (HKG:2142) Shares?

Mar 10

Revenue & Expenses Breakdown
Beta

How HBM Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SEHK:2142 Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
31 Dec 23	90	23	21	45
30 Sep 23	72	-19	21	62
30 Jun 23	54	-61	21	80
31 Mar 23	47	-99	24	108
31 Dec 22	41	-137	27	135
30 Sep 22	35	-143	35	142
30 Jun 22	30	-149	43	150
31 Mar 22	17	-144	42	128
31 Dec 21	4	-138	40	107
30 Sep 21	7	-224	46	94
30 Jun 21	10	-310	53	81
31 Mar 21	12	-303	50	68
31 Dec 20	14	-296	46	55
30 Sep 20	13	-187	28	46
30 Jun 20	11	-78	11	37
31 Mar 20	8	-73	11	43
31 Dec 19	5	-67	11	49
31 Dec 18	1	-35	6	32

Beneficios de calidad: 2142 tiene ganancias de alta calidad.

Creciente margen de beneficios: 2142 fue rentable en el pasado.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Tendencia de beneficios: 2142 se ha vuelto rentable en los últimos 5 años, con un crecimiento de los beneficios de 10.4% al año.

Acelerando crecimiento: 2142 ha pasado a ser rentable en el último año, lo que dificulta la comparación de la tasa de crecimiento de los beneficios con su media de 5 años.

Beneficios vs. Industria: 2142 ha pasado a ser rentable en el último año, lo que hace difícil comparar el crecimiento de sus beneficios en el último año con el del sector Biotechs (17.1%).

Return on Equity

Alto ROE: El Retorno sobre el capital de 2142 (19%) se considera bajo.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

HBM Holdings Past Earnings Performance

Past criteria checks 3/6

Key information

Recent past performance updates

Full year 2023 earnings released: EPS: US$0.03 (vs US$0.19 loss in FY 2022)

HBM Holdings Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

First half 2023 earnings released: EPS: US$0.004 (vs US$0.10 loss in 1H 2022)

HBM Holdings Limited to Report First Half, 2023 Results on Aug 28, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

First half 2022 earnings released: US$0.10 loss per share (vs US$0.084 loss in 1H 2021)

Recent updates

HBM Holdings Limited, Annual General Meeting, Jun 06, 2024

Full year 2023 earnings released: EPS: US$0.03 (vs US$0.19 loss in FY 2022)

HBM Holdings Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Harbour BioMed Announces IND Clearance for HBM9027 in the U.S

HBM Holdings Limited Provides Earnings Guidance for the Year Ended 31 December 2023

HBM Holdings Limited (HKG:2142) Surges 25% Yet Its Low P/S Is No Reason For Excitement

HBM Holdings Limited Announces Executive Changes

New major risk - Revenue and earnings growth

Forecast to breakeven in 2023

Consensus EPS estimates upgraded to US$0.05 loss

First half 2023 earnings released: EPS: US$0.004 (vs US$0.10 loss in 1H 2022)

Harbour BioMed Announces US IND Clearance of Its First ADC Program HBM9033 in Solid Tumors

HBM Holdings Limited to Report First Half, 2023 Results on Aug 28, 2023

Harbour BioMed Appoints Dr. Albert R. Collinson as Independent Non-Executive Director

New minor risk - Share price stability

HBM Holdings Limited Announces Board Changes

National Medical Products Administration of China Accepts Biologics License Application for HBM Holdings Limited's Batoclimab for Treatment of gMG

HBM Holdings Limited Appoints Steve Arkinstall as Chief Scientific Advisor of Nona Biosciences

Harbour BioMed Announces First Patient Dosed in Phase I Study of First-In-Class Anti-B7H7 (HHLA2) Antibody HBM1020

Harbour BioMed Reports Results of Phase Ib Clinical Trial of Porustobart in Combination of Toripalimab in Patients with Hepatocellular Carcinoma at ASCO 2023

Consensus revenue estimates increase by 28%

Consensus estimates of losses per share improve by 36%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Hbm Holdings Limited Announces Food and Drug Administration of the United States Investigational New Drug Clearance for HBM1020 Clinical Trial Initiation

Hbm Holdings Limited Announces Results from Phase I Clinical Trial of Porustobart (Hbm4003)In Combination with Toripalimab in Advanced Melanoma

WuXi Vaccines (Hong Kong) Limited entered into an agreement to acquire Manufacturing facility in Suzhou from HBM Holdings Limited (SEHK:2142).

Less than half of directors are independent

HBM Holdings Limited Appoints Mr. Weihao Xu as Chief Business Officer

Harbour BioMed Announces Dosing of First Patient in Phase I Trial of B7H4x4-1BB Bispecific Antibody in the United States

Hbm Holdings Limited Announces Closing the Study of Phase III Clinical Trial of Tanfanercept (Hbm9036)

Harbour BioMed Announces First Subject Dosed in Phase I Study of Next-Gen Anti-TSLP Fully Human Monoclonal Antibody

Consensus forecasts updated

First half 2022 earnings released: US$0.10 loss per share (vs US$0.084 loss in 1H 2021)

Hbm Holdings Limited Announces Completion of First Dosing of Last Patient with Hbm4003 Phase Ib Trial

Harbour BioMed Announces the Preclinical Results of Porustobart

HBM Holdings Limited to Report First Half, 2022 Results on Aug 31, 2022

Harbour BioMed Announces IND Clearance for B7H4x4-1BB Bispecific Antibody by the U.S. Food and Drug Administration

HBM Holdings Limited Announces IND Approval for Commencement of Phase I Trial of B7H4X4-1BB Bispecific Antibody in China

Hbm Holdings Limited Announces Data Release of Next-Gen Ctla-4 Antibody At Asco 2022

HBM Holdings Limited Announces That Dosing of First Patient in Phase I Trial of B7h4x4-1Bb Bispecific Antibody Hbm7008 Has Been Completed

Consensus forecasts updated

Hbm Holdings Limited Announces Data Release Forecast of Hbm4003 At ASCO 2022

HBM Holdings Limited Announces Board Changes

Harbour BioMed Appoints Dr. Alexander A. Zukiwski to its Scientific Advisory Board

Less than half of directors are independent

Harbour BioMed Appoints Humphrey Gardner as Chief Medical Officer

Consensus revenue estimates increase by 302%

Harbour BioMed Announces Approval for Phase I Trial of B7H4x4-1BB Bispecific Antibody in Australia

HBM Holdings Limited Announces Approval of Investigational New Drug Application for HBM9378 by National Medical Products Administration of the People's Republic of China

We're Not Very Worried About HBM Holdings' (HKG:2142) Cash Burn Rate

HBM Holdings Limited Announces Completion of First Interim Analysis of Phase III Clinical Trial of Tanfanercept (HBM9036)

Founder recently bought HK$1.0m worth of stock

HBM Holdings Limited Announces Completion of First Dosing of First Patient with Two HBM4003 Phase I Trials

HBM Holdings Limited Announces Completion of First Dosing of First Patient with Batoclimab (Hbm9161) Phase III Trial for Treatment of Generalized Myasthenia Gravis

Harbour Biomed Announces Phase I Study Positive Results on Next-Generation Anti-CTLA-4 Antibody HBM4003

HBM Holdings Limited Announces Chinese Regulatory Approval of Two Ind Applications for Next-Generation Anti-Ctla-4 Antibody Hbm4003

First half 2021 earnings released: US$0.084 loss per share (vs US$0.39 loss in 1H 2020)

HBM Holdings Limited Receives National Medical Products Administration of the People's Republic of China Approval of Investigational New Drug Application to Begin Phase II Clinical Trial of HBM9161 in Chronic Inflammatory Demyelinating Polyneuropathy

Harbour BioMed Announces Dosing of First Patient of Next-Generation Anti-CTLA-4 Antibody in Combination with PD-1 Antibody in Patients with NSCLC

HBM Holdings Limited Provides Update on Ongoing Clinical Studies Forbatoclimab (HBM9161)

HBM Holdings (HKG:2142) Is In A Strong Position To Grow Its Business

Harbour BioMed Announces Dosing of First Patient in Australia for Phase Ib/IIa Clinical Study of its Next-Generation Anti-CTLA-4 Antibody

Executive Director, Chief Strategy Officer & Head of U.S. Operations has left the company

Full year 2020 earnings released: US$1.69 loss per share (vs US$0.57 loss in FY 2019)

Revenue Downgrade: Here's What Analysts Forecast For HBM Holdings Limited (HKG:2142)

Consensus forecasts updated

Here's What Analysts Are Forecasting For HBM Holdings Limited (HKG:2142) After Its Full-Year Results

Full year 2020 earnings released: US$1.69 loss per share (vs US$0.57 loss in FY 2019)

HBM Holdings Limited Announces Update on Phase III Clinical Trial of Tanfanercept

Revenue & Expenses Breakdown
Beta